Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
You may also be interested in...
Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline
Anthera's planned offering will be the first real IPO in 18 months and a good indicator of whether there are signs of life in the biotech IPO market.
Merck took its time coming back into the flu vaccine field, but the expansion of world suppliers of vaccines brought a very well-suited partner to its doorstep